Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 3/20 | 0.30 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CDK14 | O94921 | 1/20 | 0.30 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19069390 | 0.90 | ACKR3 (0.36) | EGFRACKR3LMNA | |
| SCHEMBL20939084 | 0.90 | ACKR3 (0.36) | EGFRACKR3LMNA | |
| SCHEMBL20938920 | 0.85 | ACKR3 (0.34) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20927064 | 0.83 | KMT2A (0.43) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22355634 | 0.82 | EGFR (0.37) | EGFRACKR3LMNACHRNB2CHRNB4 | |
| SCHEMBL19912763 | 0.81 | EGFR (0.39) | EGFRACKR3LMNAERBB2 | |
| SCHEMBL24690684 | 0.80 | ALDH1A1 (0.43) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19069227 | 0.80 | ACKR3 (0.33) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21108889 | 0.80 | ACKR3 (0.33) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21889711 | 0.78 | KMT2A (0.34) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | Shanghai Pharmaceuticals Holding Cd., Ltd. (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ACKR3 829/4885LMNA 2409/4885 |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | EGFR 272/4885ACKR3 3720/4885LMNA 1523/4885 |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | EGFR 2065/4885ACKR3 1129/4885LMNA 1304/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | EGFR 201/4885ACKR3 2603/4885LMNA 2600/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | EGFR 2649/4885ACKR3 4736/4885LMNA 2907/4885 |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | EGFR 3164/4885ACKR3 1663/4885LMNA 3795/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ACKR3 829/4885LMNA 2409/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | EGFR 201/4885ACKR3 2603/4885LMNA 2600/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | EGFR 3164/4885ACKR3 1663/4885LMNA 3795/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ACKR3 829/4885LMNA 2409/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ACKR3 829/4885LMNA 2409/4885 |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | ERBB2, EGFR, ERBB4 | EGFR 2/4885ACKR3 2446/4885LMNA 2460/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | EGFR 201/4885ACKR3 2603/4885LMNA 2600/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | EGFR 3164/4885ACKR3 1663/4885LMNA 3795/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | EGFR 1023/4885ACKR3 2031/4885LMNA 4597/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | EGFR 3164/4885ACKR3 1663/4885LMNA 3795/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | EGFR 3164/4885ACKR3 1663/4885LMNA 3795/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | EGFR 1162/4885ACKR3 195/4885LMNA 3737/4885 |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | EGFR 201/4885ACKR3 2603/4885LMNA 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.